SCHEMBL6854028

SCHEMBL6854028

O=C1NC(=O)C(=Cc2ccccc2OCCn2cnc3ccccc3c2=O)S1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.57
MEN1 O00255 7/20 0.57
ALDH1A1 P00352 4/20 0.57
HTT P42858 4/20 0.57
TTR P02766 2/20 0.57
KDM4E B2RXH2 2/20 0.57
POLB P06746 2/20 0.57
BLM P54132 1/20 0.57
PLA2G1B P04054 1/20 0.57
ATG4B Q9Y4P1 1/20 0.57
SMN1; SMN2 Q16637 4/20 0.54
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
IGF1R P08069 1/20 0.51
HPGD P15428 6/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 2/20 0.48
KCNH2 Q12809 1/20 0.48
PTPN1 P18031 1/20 0.48
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5935704 0.87 HPGD (0.57) KMT2AMEN1ALDH1A1HTTPOLB
SCHEMBL6359259 0.87 HPGD (0.57) KMT2AMEN1ALDH1A1HTTPOLB
SCHEMBL9570599 0.77 MEN1 (0.74) KMT2AMEN1ALDH1A1HTTTTR
SCHEMBL9570595 0.77 MEN1 (0.74) KMT2AMEN1ALDH1A1HTTTTR
SCHEMBL2420688 0.74 MEN1 (0.70) KMT2AMEN1ALDH1A1HTTTTR
SCHEMBL2420684 0.74 MEN1 (0.70) KMT2AMEN1ALDH1A1HTTTTR
SCHEMBL2420687 0.74 MEN1 (0.70) KMT2AMEN1ALDH1A1HTTTTR
SCHEMBL29837048 0.74 HPGD (0.71) KMT2AMEN1ALDH1A1HTTTTR
SCHEMBL12155710 0.73 MEN1 (1.00) KMT2AMEN1ALDH1A1HTTTTR
SCHEMBL1247458 0.73 MEN1 (1.00) KMT2AMEN1ALDH1A1HTTTTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780992-B2 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL) -ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONE FOR EXAMPLE; ALSO OXAZOLIDINE-2,4-DIONE, AND 1,2,4-OXADIAZOLIDINE-3,5-DIONE DERIVATIVES; REDUCING BLOOD GLUCOSE LEVELS DR. REDDY'S LABORATORIES LTD. (IN) 2004-08-24 US disclosed
US-20020123502-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. 2002-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123502-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases IAPP, GPR119, CYP11B1 KMT2A 4698/4885MEN1 859/4885ALDH1A1 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.